Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas.
Effectiveness
Non-L-sarcomas
Safety
Spain
Trabectedin
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
29
11
2021
accepted:
17
01
2022
pubmed:
8
2
2022
medline:
12
4
2022
entrez:
7
2
2022
Statut:
ppublish
Résumé
The effectiveness of trabectedin for the treatment of leiomyosarcoma and liposarcoma (commonly referred to as L-sarcomas) has been widely evidenced in clinical trials and real-world studies. Nevertheless, available literature on non-L-sarcomas is less abundant. The objective of the present study is to evaluate the effectiveness and safety of trabectedin in a cohort of patients with non-L-sarcomas in the real-world setting. This retrospective, observational study included 34 patients who received trabectedin in the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) between October 2013 and July 2020. The most frequent histologic subtypes were undifferentiated spindle cell/pleomorphic sarcoma (n = 11, 32.4%), synovial sarcoma (n = 6, 17.7%), myxofibrosarcoma (n = 5, 14.7%), and malignant peripheral nerve sheath tumor (n = 4, 11.8%). The mean number of cycles with trabectedin was 5.5 (range 2-28). Three patients achieved partial response (8.8%) and eight patients showed stable disease (23.5%). The objective response rate and disease control rate were 8.8% (95% confidence interval (CI), 95% CI 1.9-23.7) and 32.4% (95% CI 17.4-50.5), respectively. Overall, progression-free survival was 2.9 months (95% CI 2.1-3.4). The overall survival was 7.3 months (95% CI 4.7-12.8). The most common trabectedin-related grade 3 adverse events were observed in 10 patients (26.5%), mostly being neutropenia (14.7%) and elevated transaminases (5.9%), whereas one patient (2.9%) reported grade 4 febrile neutropenia that required hospitalization. The findings of this real-life study consistently support that trabectedin is an effective and safe option for the treatment of patients with non-L-sarcoma after failure of anthracyclines and ifosfamide, or in patients who are unsuited to receive these agents.
Identifiants
pubmed: 35129790
doi: 10.1007/s12325-022-02051-2
pii: 10.1007/s12325-022-02051-2
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Dioxoles
0
Tetrahydroisoquinolines
0
Trabectedin
ID0YZQ2TCP
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1596-1610Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Gajdos C, Elias A. Trabectedin: safety and efficacy in the treatment of advanced sarcoma. Clin Med Insights Oncol. 2011;5:35–43.
doi: 10.4137/CMO.S4907
Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70:200–29.
doi: 10.3322/caac.21605
National Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: soft tissue including heart cancer. https://seer.cancer.gov/statfacts/html/soft.html . Accessed Aug 2021.
Savina M, Le Cesne A, Blay JY, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15:78.
doi: 10.1186/s12916-017-0831-7
European Medicines Agengy. Yondelis. https://www.ema.europa.eu/en/documents/product-information/yondelis-epar-product-information_en.pdf . Accessed Aug 2021.
Barone A, Chi DC, Theoret MR, et al. FDA approval summary: trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen. Clin Cancer Res. 2017;23:7448–53.
doi: 10.1158/1078-0432.CCR-17-0898
Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23:576–84.
doi: 10.1200/JCO.2005.01.180
Pink D, Bertz-Lepel J, Busemann C, Bitz U, Reichardt P. Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma. Onkologie. 2012;35:249–52.
doi: 10.1159/000338342
Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013;24:1703–9.
doi: 10.1093/annonc/mds659
Le Cesne A. 13 years of trabectedin, 5 years of Yondelis
doi: 10.1586/era.13.49
Blay J, Italiano A, Ray-Coquard I, et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer. 2013;13:64.
doi: 10.1186/1471-2407-13-64
Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013;30:501.
doi: 10.1007/s12032-013-0501-3
Frezza AM, Whelan JS, Dileo P. Trabectedin for desmoplastic small round cell tumours: a possible treatment option? Clin Sarcoma Res. 2014;4:3.
doi: 10.1186/2045-3329-4-3
Reichardt P, Grünwald V, Kasper B, Schuler M, Gelderblom H. Efficacy of trabectedin in patients with some rare advanced soft tissue sarcoma subtypes other than liposarcoma and leiomyosarcoma. J Med Drug Rev. 2015;5:33–42.
Khalifa J, Ouali M, Chaltiel L, et al. Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer. 2015;15:700.
doi: 10.1186/s12885-015-1697-8
Sanfilippo R, Dileo P, Blay JY, et al. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs. 2015;26:678–81.
doi: 10.1097/CAD.0000000000000228
De Sanctis R, Marrari A, Marchetti S, et al. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. Drug Des Dev Ther. 2015;9:5785–91.
doi: 10.2147/DDDT.S92395
Le Cesne A, Ray-Coquard I, Duffaud F, et al. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur J Cancer. 2015;51:742–50.
doi: 10.1016/j.ejca.2015.01.006
Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015;16:406–16.
doi: 10.1016/S1470-2045(15)70098-7
Syed I, Sudan M, Tseng W, et al. Trabectedin for advanced soft-tissue sarcoma: a single-center experience of over 10 years. J Clin Oncol. 2016;34:11052.
doi: 10.1200/JCO.2016.34.15_suppl.11052
Kobayashi H, Iwata S, Wakamatsu T, et al. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: a Japanese Musculoskeletal Oncology Group study. Cancer. 2020;126:1253–63.
doi: 10.1002/cncr.32661
de Sande González LM, Martin-Broto J, Kasper B, Blay JY, Le Cesne A. Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. Expert Rev Anticancer Ther. 2020;20:957–63.
doi: 10.1080/14737140.2020.1822744
Palmerini E, Sanfilippo R, Grignani G, et al. Trabectedin for patients with advanced soft tissue sarcoma: a non-interventional, retrospective, multicenter study of the Italian Sarcoma Group. Cancers (Basel). 2021;13:1053.
doi: 10.3390/cancers13051053
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
doi: 10.1016/j.ejca.2008.10.026
Buonadonna A, Benson C, Casanova J, et al. A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. Anticancer Drugs. 2017;28:1157–65.
doi: 10.1097/CAD.0000000000000560
Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38:543–9.
doi: 10.1016/S0959-8049(01)00398-7
Morioka H, Takahashi S, Araki N, et al. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer. 2016;14(16):479.
doi: 10.1186/s12885-016-2511-y
Stacchiotti S, Dagrada GP, Sanfilippo R, et al. Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. Clin Sarcoma Res. 2013;3:16.
doi: 10.1186/2045-3329-3-16
Chiusole B, Le Cesne A, Rastrelli M, et al. Extraskeletal myxoid chondrosarcoma: clinical and molecular characteristics and outcomes of patients treated at two institutions. Front Oncol. 2020;16(10):828.
doi: 10.3389/fonc.2020.00828
Stacchiotti S, Ferrari S, Redondo A, et al. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;20:1252–62.
doi: 10.1016/S1470-2045(19)30319-5